Florence Agyemang-Bioh

Mrs. Florence Agyemang-Bioh

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
RKRichard Kutame
Richard Kutame
GBGifty Boateng
Gifty Boateng
YAYaw Adusi-Poku
Yaw Adusi-Poku
FSFelix Sorvor
Felix Sorvor
LALorreta Antwi
Lorreta Antwi
FAFranklin Asiedu-Bekoe
Franklin Asiedu-Bekoe
Interferon-gamma release assays (IGRAs) have gained attention for the diagnosis of latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, the IGRA’s performance varies across different populations. This study evaluated the diagnostic performance of three IGRAs (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays as per the manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had sensitivity of 78.5–87.3% and specificity of 82.9–90.0%. These findings indicate that while the three IGRAs offer similar diagnostic accuracy, the variations in specificity and limited data on assays like TBF-FIA require further investigation.

1 January 2026 in Advances in Public Health
Verified
Journal Article
Open access
RKRichard Kutame
Richard Kutame
GBGifty Boateng
Gifty Boateng
VBVincent Gyau Boateng
Vincent Gyau Boateng
FAFlorence Agyemang-Bioh
Florence Agyemang-Bioh
LALorreta Antwi
Lorreta Antwi
RARexford Adade
Rexford Adade
Background: The diagnosis of Mycobacterium tuberculosis infection increasingly relies on interferon‐gamma release assay (IGRA) technologies. Despite their usefulness, inconsistency in IFN‐ γ responses and the persistence of indeterminate results remain problematic across IGRA platforms. The present study aimed to comparatively assess three commercial IGRA assays (TBF‐ELISA, TBF‐FIA, and QFT‐Plus) with emphasis on IFN‐ γ production and factors influencing indeterminate results. Methods: The study employed a cross‐sectional design and was implemented at the National Public Health and Reference Laboratory in Ghana. A total of 1148 individuals were enrolled consecutively and stratified according to their TB exposure status. Parallel testing of collected blood samples was performed with the three IGRA assays. IFN‐ γ production was quantified, and the rate of indeterminate results was analyzed. Multivariate regression analyses were performed to assess determinants of IFN‐ γ levels and indeterminate results. Results: Significant quantitative differences in IFN‐ γ responses were observed across platforms ( p < 0.001). Active TB was the strongest predictor of IFN‐ γ release, with highest mean levels detected by TBF‐FIA (6.18 IU/mL), followed by TBF‐ELISA (3.11 IU/mL) and QFT‐Plus (2.80–2.96 IU/mL). TBF‐ELISA showed strong concordance with minimal bias versus QFT‐Plus (≤0.167 IU/mL), whereas TBF‐FIA demonstrated substantial proportional bias (>1.5 IU/mL). Indeterminate rates differed significantly (TBF‐FIA 13%, QFT‐Plus 8%, TBF‐ELISA 6%; Cochran’s Q test, p < 0.001). Demographic factors were not associated with assay failure; however, sample collection sites were significantly related. Notably, healthcare workers and TB contacts showed lower IFN‐ γ responses than expected. Conclusion: While all three IGRAs effectively differentiate TB infection status, the variability in IFN‐ γ responses and indeterminate rates is an indication that they may not be interchangeable. TBF‐FIA demonstrated the highest variability, requiring further investigation. The findings suggest that each test has its own strengths and limitations, thus, the need for selective use depending on the clinical setting and testing purpose.

22 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
RKRichard Kutame
Richard Kutame
GBGifty Boateng
Gifty Boateng
YAYaw Adusi-Poku
Yaw Adusi-Poku
FSFelix Sorvor
Felix Sorvor
LALorreta Antwi
Lorreta Antwi
FAFranklin Asiedu-Bekoe
Franklin Asiedu-Bekoe
Interferon-gamma release assays (IGRAs) gained attention for diagnosing latent tuberculosis infection (LTBI) due to their higher specificity compared to the tuberculin skin test (TST). However, IGRA performance varied across different populations. This study evaluated the diagnostic performance of three IGRA assays (TBF-FIA, TBF-ELISA, and QFT-Plus) in Ghana, comparing them among individuals exposed and unexposed to MTB infection. Conducted in TB clinics across three regions, this prospective and cross-sectional study included healthy individuals with no known TB exposure (unexposed group) and patients with confirmed active TB (exposed group). Blood samples were tested using all three assays per manufacturers’ guidelines. The TBF-ELISA showed 3.4% higher sensitivity, but 4.6% lower specificity compared to QFT-Plus. The TBF-FIA had a sensitivity of 78.5%-87.3% and a specificity of 82.9%-90.0%. These findings indicated that while the three IGRA assays offered similar diagnostic accuracy, variations in specificity and limited data on point-of-care assays like TBF-FIA required further investigation.